Abstract
The immunofluorescent reaction of peripheral blood cells from 10 multiple myeloma, 10 Hodgkin's and 11 lymphosarcoma cases with antiviral (Rauscher) murine leukaemia (AMR) and antihuman stem cell leukaemia plasma (AHS) antisera was studied. Cells from 25 of these patients were reactive at least once with AMR and AHS or AHS alone. Absorption studies suggested that this cytoplasmic immunofluorescent reaction involved cellular isoantigens. Serial studies on multiple myeloma, Hodgkin's and lymphosarcoma cases with significant fluorescence, showed that the fluorescent cell count variation was correlated with the presence of active disease.
Highlights
Summary.-The immunofluorescent reaction of peripheral blood cells from 10 multiple myeloma, Hodgkin's and lymphosarcoma cases with antiviral (Rauscher) murine leukaemia (AMR) and antihuman stem cell leukaemia plasma (AHS) antisera was studied
PREVIOUS studies (Fink et al, 1965; Joannides, Rosner and Lee, 1968; Bates, Bankole and Swaim, 1969) reported that blood cells from patients with Hodgkin's disease, multiple myeloma, and other lymphomata fluoresced when reacted with antimurine leukaemia virus (Rauscher) or antihuman leukaemia plasma antiserum
In another report (Swaim et al, 1971) the onset of myelogenous leukaemia in a patient with Hodgkin's disease was characterized by the appearance of nucleated peripheral blood cells which fluoresced when reacted with the above described leukaemia antiserum
Summary
Leukocytes from 30 individuals with normal blood cell morphology and counts were pooled and triturated on a Ten Broeck grinder. To this material was added an equal volume of phosphate (0-10 mol/l) buffered saline (0a15 mol/1) pH 7-2 (PBS). To 2 ml of conjugated serum (AMR or AHS) was added 0-2 ml of the cellular extract. This mixture was reacted at 37°C for 2 hours with occasional shaking and centrifuged at 5000 g for 60 min. Additional " immunological blocking" reactions were carried out by reacting absorbed, unconjugated AMR and AHS with nucleated blood cells of multiple myeloma, Hodgkin's and lymphosarcoma cases
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
